Celsion to Initiate Phase 1/2 Trial of GEN-1 in Newly-diagnosed Ovarian Cancer Patients

Celsion to Initiate Phase 1/2 Trial of GEN-1 in Newly-diagnosed Ovarian Cancer Patients
A Phase 1/2 trial to evaluate the DNA-based immunotherapy GEN-1 in patients with newly-diagnosed advanced ovarian cancer has been cleared by the U.S. Food and Drug Administration (FDA) without restrictions, Celsion announced. Recruitment for Phase 1 of the trial, called OVATION II (NCT03393884), is expected to begin by July this year and reach 25 percent of the enrollment

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *